Dr. Reddy’s announces the Launch of LEVALBUTEROL INHALATION SOLUTION,
FOR ORAL INHALATION ONLY
Hyderabad, India, September 24, 2014
We are happy to launch Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX® (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
The XOPENEX® (levalbuterol hydrochloride) inhalation solution brand and generic combined had U.S. sales of approximately $269.7 Million MAT for the most recent twelve months ending in June 2014 according to IMS Health*.
Dr. Reddy’s Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg /3 mL are available in Unit-Dose Vials of (5 x 3 mL) carton of 25. Levalbuterol Inhalation Solution, USP is only for use with a nebulizer.
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets. For more information, log on to: www.drreddys.com
XOPENEX® is a registered trademark of Sunovion Pharmaceuticals Inc.
*IMS National Sales Perspectives: Retail and Non-Retail MAT June 2014
For more information please contact:
Investors and Financial Analysts:
Kedar Upadhye at email@example.com / +91-40-66834297
Saunak Savla at firstname.lastname@example.org / +91-40-49002135
Ashish Girotra (USA) at email@example.com / +1 609-375-9805
Shilpi Lathia at firstname.lastname@example.org / +91-40-49002448